Q2 EPS Forecast for Tenax Therapeutics Lowered by Analyst

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Research analysts at Roth Capital lowered their Q2 2025 EPS estimates for Tenax Therapeutics in a research report issued to clients and investors on Wednesday, May 14th. Roth Capital analyst J. Aschoff now forecasts that the specialty pharmaceutical company will post earnings per share of ($0.19) for the quarter, down from their previous estimate of ($0.18). The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Roth Capital also issued estimates for Tenax Therapeutics’ Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.89) EPS, FY2026 earnings at ($0.94) EPS and FY2027 earnings at ($0.96) EPS.

Several other equities research analysts also recently issued reports on the stock. Guggenheim reissued a “buy” rating and set a $15.00 price objective on shares of Tenax Therapeutics in a research report on Thursday, May 15th. William Blair reissued an “outperform” rating on shares of Tenax Therapeutics in a research report on Monday, March 10th. Leerink Partners set a $20.00 price objective on shares of Tenax Therapeutics in a research report on Monday, March 10th. Finally, StockNews.com started coverage on shares of Tenax Therapeutics in a research report on Friday, May 16th. They set a “sell” rating for the company. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $17.50.

Tenax Therapeutics Stock Down 0.3%

Shares of TENX stock opened at $6.00 on Monday. The firm has a fifty day moving average of $5.85 and a 200-day moving average of $5.93. Tenax Therapeutics has a 12-month low of $2.77 and a 12-month high of $7.89. The company has a market capitalization of $24.89 million, a price-to-earnings ratio of -2.42 and a beta of 1.92.

Tenax Therapeutics (NASDAQ:TENX) last announced its earnings results on Wednesday, May 14th. The specialty pharmaceutical company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.20.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC bought a new position in shares of Tenax Therapeutics in the 4th quarter valued at $1,026,000. ADAR1 Capital Management LLC lifted its stake in shares of Tenax Therapeutics by 98.1% in the 1st quarter. ADAR1 Capital Management LLC now owns 68,741 shares of the specialty pharmaceutical company’s stock valued at $450,000 after acquiring an additional 34,048 shares during the last quarter. Millennium Management LLC bought a new position in shares of Tenax Therapeutics in the 4th quarter valued at $166,000. Geode Capital Management LLC lifted its stake in shares of Tenax Therapeutics by 32.4% in the 4th quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock valued at $151,000 after acquiring an additional 5,964 shares during the last quarter. Finally, Two Sigma Investments LP bought a new stake in shares of Tenax Therapeutics during the fourth quarter worth about $84,000. Institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.